Online Exclusive

Chemotherapy & Immunotherapy Effective in Phase II Leukemia Study

A combination of azacitidine and nivolumab demonstrated an encouraging response rate and OS in patients with relapsed or refractory AML. 

FDA Alert

NEW APPROVAL: Treatment for Patients With Acute Myeloid Leukemia

Glasdegib tablets in combination with LDAC for newly-diagnosed acute myeloid leukemia.

Your Career Path

How to Successfully Navigate the Research Grant Process

Research grants are vital not just for the professional development of individual clinicians, but also for ongoing discovery in the field.

Featured Articles

Immunotherapy Shows Promise in Treatment of Hodgkin Lymphoma​

By Catlin Nalley

Immunotherapy continues to gain momentum across a multitude of cancer types and lymphoma is no exception.​

ASCO Names CAR T-Cell Immunotherapy 2018 Advance of the Year

By Peggy Eastman

The FDA approved CAR T-cell therapy in 2017 to treat adults with DLBCL, as well as children and young adults with ALL.​

Applying Genomics to Leukemias & Lymphomas​

By Ankur R. Parikh, DO

Utilization of next-generation sequencing in clinical hematologic oncology practice is rapidly rising.​

From the Issue

Ultra-Rare Cancers: Opening Doors to Therapeutic Discovery

Rare cancers once were the forgotten cousins of diseases known to impact larger populations. Fortunately, medical thinking has evolved, and the way rare diseases are considered is rapidly changing.

Options Emerge for Relapsed/Refractory Hodgkin Lymphoma

Multiple options are emerging for the treatment of third-line Hodgkin lymphoma (HL), including repurposed drugs, HL-specific drugs, and CAR T-cell therapy.

Editorial

Rare Blood Cancers in 2018 & Beyond

A surprisingly high number of scientific observations and discoveries in the hematology/oncology world have in fact been made in more rare disease entities first, then studied, and upon further investigation, subsequently applied to more common tumor types.